Form 20-F/A BioNTech SE For: Dec 31
http://archive.fast-edgar.com/20260730/AQVZC22CZ22FB2Z2222B22ZNGDQDZZ229Y82
Filed on: July 30, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
- BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
- Primary Sclerosing Cholangitis Pipeline Update 2026: Clinical Development Status, Collaborations, and Key Companies to Watch | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharma
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share